ESR1 and breast cancer: Osipo et al. [140] revealed that in Trastuzumab-treated, HER-2-positive or Tamoxifen-treated estrogen receptor (ER)-positive human mammary tumors, the NOTCH1 pathway that is initially inactivated is turned on after a long period of chemotherapy.